Search results for "PARKIN"

showing 10 items of 468 documents

Myofibrillar disorganization characterizes myopathy of camptocormia in Parkinson’s disease

2011

Camptocormia is a highly disabling syndrome that occurs in various diseases but is particularly associated with Parkinson’s disease (PD). Although first described nearly 200 years ago, the morphological changes associated with camptocormia are still under debate and the pathophysiology is unknown. We analyzed paraspinal muscle biopsies of 14 PD patients with camptocormia and compared the findings to sex-matched postmortem controls of comparable age to exclude biopsy site-specific changes. Camptocormia in PD showed a consistent lesion pattern composed of myopathic changes with type-1 fiber hypertrophy, loss of type-2 fibers, loss of oxidative enzyme activity, and acid phosphatase reactivity …

MalePathologymedicine.medical_specialtyParkinson's diseaseMyopathyClinical Neurology610BiologySpinal CurvaturesMuscle hypertrophyPathology and Forensic MedicineLesionMuscular Atrophy Spinal03 medical and health sciencesCamptocormiaMyofibrillar disorganizationCellular and Molecular Neuroscience0302 clinical medicineMyofibrilsBiopsymedicineHumansProspective StudiesMyopathyMuscle SkeletalParkinson’s disease; Camptocormia; Myopathy; Myofibrillar disorganization; ProprioceptionMyositis030304 developmental biologyAgedAged 80 and over0303 health sciencesOriginal Papermedicine.diagnostic_testParkinson DiseaseMiddle Agedmedicine.diseaseProprioceptionPathophysiologyCamptocormiaParkinson’s diseaseFemaleNeurology (clinical)medicine.symptomMedicine & Public Health; Neurosciences; Pathology030217 neurology & neurosurgeryActa Neuropathologica
researchProduct

A Strange Case of Downward Displacement of a Deep Brain Stimulation Electrode 10 Years Following Implantation: The Gliding Movement of Snakes Theory.

2014

Background Despite the best efforts to ensure stereotactic precision, deep brain stimulation (DBS) electrodes can wander from their intended position after implantation. We report a case of downward electrode migration 10 years following successful implantation in a patient with Parkinson disease. Methods A 53-year-old man with Parkinson disease underwent bilateral implantation of DBS electrodes connected to a subclavicular 2-channel pulse generator. The generator was replaced 7 years later, and a computed tomography (CT) scan confirmed the correct position of both leads. The patient developed a gradual worsening affecting his right side 3 years later, 10 years after the original implantati…

MaleReoperationDeep brain stimulationmedicine.medical_treatmentDeep Brain StimulationComputed tomographyPostoperative ComplicationsDeep brain stimulation electrodeForeign-Body MigrationSubthalamic NucleusPonsMedicineHumansDisplacement (orthopedic surgery)DBS complicationmedicine.diagnostic_testSettore MED/27 - Neurochirurgiabusiness.industryForeign-Body ReactionGranuloma Foreign-BodyParkinson DiseaseEquipment DesignMiddle AgedElectrodes ImplantedSurgeryElectrode displacementNeurology (clinical)Nuclear medicinebusinessTomography X-Ray ComputedDownward displacementWorld neurosurgery
researchProduct

Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson’s disease

2011

Mitochondrial dysfunction and oxidative stress occur in Parkinson’s disease (PD), but little is known about the molecular mechanisms controlling these events. Peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α) is a transcriptional coactivator that is a master regulator of oxidative stress and mitochondrial metabolism. We show here that transgenic mice overexpressing PGC-1α in dopaminergic neurons are resistant against cell degeneration induced by the neurotoxin MPTP. The increase in neuronal viability was accompanied by elevated levels of mitochondrial antioxidants SOD2 and Trx2 in the substantia nigra of transgenic mice. PGC-1α overexpression also protected against MP…

MaleSOD2Mice TransgenicSubstantia nigraMitochondrionBiologyNeuroprotectionCell LineMiceCellular and Molecular Neurosciencechemistry.chemical_compoundDopaminemedicineAnimalsNeurotoxinParkinson Disease SecondaryMolecular BiologyPGC-1α RSV SIRT1 MPTP Dopaminergic neurons Parkinson’s diseasePharmacologyMPTPDopaminergicBrainParkinson DiseaseCell BiologyPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaMitochondriaCell biologyDisease Models AnimalOxidative Stressnervous systemBiochemistrychemistry1-Methyl-4-phenyl-1236-tetrahydropyridineTrans-ActivatorsMolecular MedicineFemaleTranscription Factorsmedicine.drugCellular and Molecular Life Sciences
researchProduct

Neurotransmitter receptor density changes in Pitx3ak mice – A model relevant to Parkinson’s disease

2014

Abstract Parkinson’s disease (PD) is the second most common neurodegenerative disorder, characterized by alterations of nigrostriatal dopaminergic neurotransmission. Compared to the wealth of data on the impairment of the dopamine system, relatively limited evidence is available concerning the role of major non-dopaminergic neurotransmitter systems in PD. Therefore, we comprehensively investigated the density and distribution of neurotransmitter receptors for glutamate, GABA, acetylcholine, adrenaline, serotonin, dopamine and adenosine in brains of homozygous aphakia mice being characterized by mutations affecting the Pitx3 gene. This genetic model exhibits crucial hallmarks of PD on the ne…

MaleSerotoninmedicine.medical_specialtyAdenosineEpinephrineDopamineMice TransgenicD1-like receptorKainate receptorBiologySerotonergicParkinsonian DisordersNeurotransmitter receptorInternal medicinemedicineAnimalsReceptorgamma-Aminobutyric Acid5-HT receptorHomeodomain ProteinsGeneral NeuroscienceHomozygoteGlutamate receptorBrainAcetylcholineReceptors NeurotransmitterMice Inbred C57BLEndocrinology5-HT6 receptorNeuroscienceTranscription FactorsNeuroscience
researchProduct

Pallidotomy improves quality of life in selected parkinsonian patients: an Italian report.

1998

Pallidotomy has recently been reconfirmed as effective for otherwise intractable symptoms of Parkinson's disease. Nonetheless almost every aspect of its performance requires choices which are not fully established and may vary between centers. These include: 1) patient selection; 2) choice of imaging modality, 3) choice of anatomic landmarks for targeting the lesion, 4) choice of method for physiologic confirmation of location, 5) choice of lesion size and shape. We present two cases of pallidotomy procedures in Parkinsonian patients that in our knowledge are the first reported in Italy. Our experience and a careful review of the literature led to the following choices: 1) selection of Park…

MaleSettore MED/27 - NeurochirurgiaNeurosurgeryMiddle AgedGlobus PallidusMagnetic Resonance ImagingSeverity of Illness IndexLevodopaItalyPallidotomy Parkinson disease surgical treatment movement diseaseQuality of LifeHumansPostoperative PeriodParkinson Disease Secondary
researchProduct

Different methods for anatomical targeting.

2003

AIM: Several procedures are used in the different neurosurgical centers in order to perform stereotactic surgery for movement disorders. At the moment no procedure can really be considered superior to the other. We contribute with our experience of targeting method. METHODS: Ten patients were selected, in accordance to the guidelines for the treatment of Parkinson disease, and operated by several methods including pallidotomy, bilateral insertion of chronic deep brain electrodes within the internal pallidum and in the subthalamic nucleus (18 procedures). Interventions: in each patient an MR scan was performed the day before surgery. Scans were performed axially parallel to the intercommissu…

MaleSettore MED/27 - NeurochirurgiaParkinson DiseaseMiddle AgedGlobus PallidusMagnetic Resonance ImagingNeurosurgical ProceduresCerebral AngiographyStereotaxic TechniquesSurgery Computer-AssistedDBS movement disorders stereotactic neurosurgerySubthalamic NucleusCerebrovascular CirculationBlood VesselsHumansFemaleTomography X-Ray ComputedAgedJournal of neurosurgical sciences
researchProduct

Sleep quality in caregivers of patients with Alzheimer’s disease and Parkinson’s disease and its relationship to quality of life

2012

ABSTRACTBackground: Knowledge about sleep complaints of caregivers of patients with Alzheimer's disease (AD) and Parkinson's disease (PD) is limited, and we lack information about the relationship between caregivers’ sleep problems and their quality of life (QoL).Methods: We evaluated subjective sleep quality and its relationship to QoL in a group of 80 caregivers of patients with AD (ADCG, n = 40) and PD (PDCG, n = 40), and in 150 controls. Information about night-time complaints was collected using the Pittsburgh Sleep Quality Index (PSQI). QoL was measured using the McGill QoL Questionnaire.Results: Eighteen ADCG (45%), 22 PDCG (55%), and 45 (30%) controls reported poor sleep quality. Me…

MaleSleep Wake DisordersCoping (psychology)medicine.medical_specialtyParkinson's diseaseDiseaseSleep Wake DisordersSeverity of Illness IndexPittsburgh Sleep Quality IndexCost of IllnessAlzheimer DiseaseSickness Impact ProfileSurveys and QuestionnairesSeverity of illnessMedicineHumansAgedAged 80 and overAlzheimer’s disease Parkinson’s disease neurodegenerative disorders caregivers sleep depression quality of lifebusiness.industryDepressionParkinson DiseaseMiddle Agedmedicine.diseasePsychiatry and Mental healthClinical PsychologySleep deprivationCaregiversItalyPhysical therapyQuality of LifeRegression AnalysisSleep DeprivationFemaleSettore MED/26 - NeurologiaSelf ReportGeriatrics and Gerontologymedicine.symptomAlzheimer's diseasebusinessGerontologyStress Psychological
researchProduct

The effects of transdermal rotigotine on non-motor symptoms of Parkinson's disease: a multicentre, observational, retrospective, post-marketing study

2017

This study evaluated the effect of ≥6 months of transdermal rotigotine on non-motor and motor symptoms of patients with advanced Parkinson's disease.The study was conducted in Spain between September 2011 and December 2012 (ClinicalTrials.gov: NCT01504529). The primary efficacy variable was the change from baseline in non-motor symptoms, as assessed by changes in Parkinson's Disease Non-Motor Symptoms Questionnaire total scores at 6 months. Secondary endpoints included the assessment of motor symptoms by Unified Parkinson's Disease Rating Scale III scores.Data from 378 patients (mean age: 70.2 years; 56.9% male) with Parkinson's disease receiving rotigotine from were collected. Mean disease…

MaleSleep Wake Disordersmedicine.medical_specialtyParkinson's diseaseTetrahydronaphthalenesThiophenesDiseaseAdministration CutaneousMotor symptoms03 medical and health sciences0302 clinical medicineSurveys and QuestionnairesProduct Surveillance PostmarketingmedicineHumans030212 general & internal medicineAgedRetrospective StudiesTransdermalAged 80 and overbusiness.industryGeneral NeuroscienceParkinson DiseaseRotigotineGeneral MedicineUrination Disordersmedicine.diseaseClinical PracticeTreatment OutcomeSpainDopamine AgonistsPhysical therapyNon motorFemaleObservational studyCognition Disordersbusiness030217 neurology & neurosurgerymedicine.drugInternational Journal of Neuroscience
researchProduct

The Role of Recollection and Familiarity in Nondemented Parkinson's Patients

2017

The aim of the current study was to examine if recollection and familiarity decline in nondemented Parkinson's patients. To do so we compared a sample of older people with Parkinson's disease (n = 32) to a control sample of healthy older people (n = 32) on an associative recognition task in which we manipulated the repetition of the pairs during the study phase (half of the pairs were presented once and half twice) to obtain corrected estimates of recollection, familiarity, and false recognition based on the logic of the process-dissociation procedure. The results clearly show that recollection is impaired but familiarity is preserved in nondemented Parkinson's patients. The results show th…

MaleStudy phaseParkinson's diseaseExperimental and Cognitive PsychologyNeuropsychological Tests050105 experimental psychologyGender Studies03 medical and health sciences0302 clinical medicineArts and Humanities (miscellaneous)medicineHumans0501 psychology and cognitive sciencesControl sampleAgedAged 80 and overRecall05 social sciencesParkinson DiseaseRecognition PsychologyMiddle Agedmedicine.diseaseFalse recognitionMental RecallFemaleOlder peoplePsychology030217 neurology & neurosurgeryCognitive psychologyThe Journal of General Psychology
researchProduct

High-frequency rTMS improves time perception in Parkinson disease.

2004

Patients with Parkinson disease (PD) are impaired in time processing. The authors investigated the effects of high-frequency (5 Hz) repetitive transcranial magnetic stimulation (rTMS) in patients with PD performing a time reproduction task. The authors found significant improvement in time processing induced by rTMS when trains were applied over the right dorsolateral prefrontal cortex (DLPFC) but not over the supplementary motor area, suggesting that the circuit involving the basal ganglia and the DLPFC might constitute the neural network subserving time perception.

MaleTRANSCRANIAL MAGNETIC STIMULATIONCORTEXmedicine.medical_treatmentmedia_common.quotation_subjectFrontal Lobe; Magnetics; Parkinson Disease; Humans; Treatment Outcome; Aged; Time Perception; Middle Aged; Prefrontal Cortex; Perceptual Disorders; Male; FemalePrefrontal CortexDiseasebehavioral disciplines and activitiesNOCentral nervous system diseasePerceptual DisordersMagneticsDegenerative diseasePerceptionmental disordersBasal gangliamedicineHumansmedia_commonAgedSupplementary motor areaSettore M-PSI/02 - Psicobiologia E Psicologia FisiologicaParkinson DiseaseTime perceptionMiddle Agedmedicine.diseaseFrontal LobeTranscranial magnetic stimulationmedicine.anatomical_structureTreatment Outcomenervous systemTime PerceptionSettore MED/26 - NeurologiaFemaleNeurology (clinical)PsychologyNeurosciencepsychological phenomena and processesNeurology
researchProduct